Association of Early Favipiravir Use with Reduced COVID-19 Fatality among Hospitalized Patients

BACKGROUND: The antiviral agent favipiravir is an RNA-dependent RNA polymerase (RdRp) inhibitor. MATERIALS AND METHODS: We examined patients with a clinical, laboratory, and radiological diagnosis of severe coronavirus disease 2019 (COVID-19) pneumonia. We investigated the effect of administering en...

Descripción completa

Detalles Bibliográficos
Autores principales: Karatas, Ercan, Aksoy, Lacin, Ozaslan, Ersin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258292/
https://www.ncbi.nlm.nih.gov/pubmed/34216123
http://dx.doi.org/10.3947/ic.2020.0149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258292/
https://www.ncbi.nlm.nih.gov/pubmed/34216123
http://dx.doi.org/10.3947/ic.2020.0149

Ejemplares similares